News
AOP Orphan: PAH Treatment for patients in Argentina
26. 1. 2021AOP Orphan announces five-year results on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) Annual Meeting 2020
7. 12. 2020ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi® (Ropeginterferon alpha-2b)
27. 10. 2020
Meet Us Globally
Show more
From the Concept to the Drug
AOP Orphan headquarters team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Orphan headquarters using the link below.